Michael Bloomfield
Professor of Psychiatric Neuroscience; Consultant Psychiatrist
Data updated
Research Footprint
Michael Bloomfield appears in 5 tracked papers (2013–2022), most studied alongside Psilocybin, MDMA and Ketamine, across Depressive Disorders, Substance Use Disorders (SUD) and Alcohol Use Disorder (AUD).
Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).
Frequent co-authors: Valerie Curran, Robin Carhart-Harris and David Nutt.
Background & Research
Michael Bloomfield is a British psychiatrist and academic researcher at University College London. He leads UCL’s Translational Psychiatry research group and works clinically as a consultant psychiatrist at UCL/UCLH. His research focuses on the neurobiology and treatment of psychiatric disorders, including studies involving psychedelics and other psychoactive compounds.
Key Impact
He is a leading UCL psychiatrist and psychedelic science researcher whose work spans ketamine, psilocybin, MDMA, and the neurobiology of mental illness.
Collaboration Network
18 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Michael Bloomfield is associated with.